Cosentyx is a medication that is used to treat psoriasis, psoriatic arthritis, and ankylosing spondylitis. The active ingredient in Cosentyx is secukinumab, which works by blocking a protein called interleukin-17A that is involved in inflammation. Although Cosentyx is generally considered to be safe and effective, there are some potential side effects that may be more common in elderly patients.

According to Drug Patent Watch [1], the most common side effects of Cosentyx are infections, such as upper respiratory tract infections and fungal infections, as well as injection site reactions, such as redness, swelling, and pain. However, elderly patients may be more susceptible to infections due to a weakened immune system, so they should be closely monitored for any signs of infection while taking Cosentyx.

A study published in the Journal of the European Academy of Dermatology and Venereology [2] found that elderly patients (defined as those over 65 years of age) were more likely to experience adverse events while taking Cosentyx than younger patients. However, the study also found that the overall safety profile of Cosentyx was similar in elderly and younger patients, and that the medication was generally well-tolerated in both groups.

Another study published in the Journal of Clinical and Aesthetic Dermatology [3] found that Cosentyx was effective in treating psoriasis in elderly patients, with no significant differences in safety or efficacy compared to younger patients. The study also noted that elderly patients may require lower doses of Cosentyx due to age-related changes in drug metabolism and clearance.

In conclusion, while Cosentyx is generally considered to be safe and effective in elderly patients, they may be more susceptible to infections and adverse events while taking the medication. Elderly patients should be closely monitored for any signs of infection or adverse events while taking Cosentyx, and may require lower doses of the medication due to age-related changes in drug metabolism and clearance.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://pubmed.ncbi.nlm.nih.gov/29404966/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5847154/